Dr Reddys Laboratories Share Price Today - Live Blog for July 30, 2025

Dr Reddys Laboratories Ltd stock price decreased by -0.05%, with the current market value at ₹1,292.00 per share. Investors are assessing the stock's potential for recovery and future growth prospects.

Dr Reddys Laboratories Ltd witnessed a notable 0.24% surge in its share price and is presently trading at ₹1,294.00, captivating the attention of market participants.

After a notable 0.12% increase, Dr Reddys Laboratories Ltd's shares are now trading at ₹1,290.20. This surge signifies heightened investor interest in acquiring the stock. The stock has a debt to equity ratio of 0.1394 and an ROE of 16.8559%.

Dr Reddys Laboratories Ltd's shares experienced a 0.12% uptick, and they are currently valued at ₹1,290.20, making it an attractive choice for investors. The stock has a debt to equity ratio of 0.1394 and an ROE of 16.8559%.

Dr Reddys Laboratories Ltd's share price rallied by 0.23%, reaching the current market price of ₹1,289.95. This surge is indicative of the stock's recent positive performance.

In the financial arena, Dr Reddys Laboratories Ltd's stock price has increased by 0.22%, with its current market value per share resting at ₹1,286.95. This development highlights the stock's appeal to investors.

Dr Reddys Laboratories Ltd has had quite the run lately, experiencing a substantial 0.00% uptick in its share price. As a result, it's now actively trading at ₹1,284.65 per share, making it an attractive option for investors.

Dr Reddys Laboratories Ltd witnessed a substantial 0.00% increase in its share price and is currently trading at ₹1,284.65. This remarkable performance has caught the eye of investors.

Dr Reddys Laboratories Ltd's share price has fallen by -0.03%, presenting both challenges and opportunities for investors. As of now, it's trading at ₹1,285.40, and market participants are assessing the implications. The stock has a PE ratio of 19.1000, an ROE of 16.8559% and a debt to equity ratio of 0.1394.

After a -0.09% decline, Dr Reddys Laboratories Ltd shares are now trading at ₹1,285.55. The stock has a PE ratio of 19.1000, an ROE of 16.8559% and a debt to equity ratio of 0.1394.

Dr Reddys Laboratories Ltd's share price has fallen by -0.06%, presenting both challenges and opportunities for investors. As of now, it's trading at ₹1,286.70, and market participants are assessing the implications. The stock has a PE ratio of 19.1000, an ROE of 16.8559% and a debt to equity ratio of 0.1394.

The share price of Dr Reddys Laboratories Ltd soared by an impressive 0.05%, marking a substantial gain for investors. At present, this stock can be acquired at a current market price of ₹1,287.50 per share.

The stock of Dr Reddys Laboratories Ltd suffered a -0.10% decline, and it currently trades at ₹1,286.05 per share. Investors are closely monitoring this situation, looking for potential signs of recovery.

Dr Reddys Laboratories Ltd witnessed a -0.28% decrease in its share price, and it is currently trading at ₹1,287.30. This decline has prompted discussions among investors regarding the stock's performance and outlook. The stock has a PE ratio of 19.1000, an ROE of 16.8559% and a debt to equity ratio of 0.1394.

In a noteworthy development, Dr Reddys Laboratories Ltd witnessed a remarkable 0.20% increase in its share price. This surge in value has sparked heightened investor interest, with the stock currently trading at ₹1,292.10 per share. The stock has an ROE of 16.8559% and debt to equity ratio of 0.1394.

Increased investor interest has propelled Dr Reddys Laboratories Ltd's stock to a significant 0.20% gain, with the share price now at ₹1,292.10. Notably, the stock's PE ratio stands at 19.1000, and its Return on Equity (ROE) is 16.8559%.

In a noteworthy development, Dr Reddys Laboratories Ltd witnessed a remarkable 0.32% increase in its share price. This surge in value has sparked heightened investor interest, with the stock currently trading at ₹1,291.15 per share. The stock has an ROE of 16.8559% and debt to equity ratio of 0.1394.

Dr Reddys Laboratories Ltd's shares experienced a 0.32% uptick, and they are currently valued at ₹1,291.15, making it an attractive choice for investors. The stock has a debt to equity ratio of 0.1394 and an ROE of 16.8559%.

Dr Reddys Laboratories Ltd observed a remarkable 0.03% surge in its share price and is presently trading at ₹1,287.00. The increased investor interest is driving this surge.

Dr Reddys Laboratories Ltd witnessed a notable 0.03% surge in its share price and is presently trading at ₹1,286.35, captivating the attention of market participants.

The stock of Dr Reddys Laboratories Ltd is making significant strides, boasting a 0.62% increase and currently trading at ₹1,286.50 per share. This upward trajectory is turning heads in the market.

Demonstrating a commendable 0.62% gain, Dr Reddys Laboratories Ltd's share price is currently situated at ₹1,286.50. In terms of valuation, the stock maintains a PE ratio of 19.1000, while the industry PE ratio stands at 35.5773.

Dr Reddys Laboratories Ltd's share price has fallen by -0.09%, presenting both challenges and opportunities for investors. As of now, it's trading at ₹1,280.00, and market participants are assessing the implications. The stock has a PE ratio of 19.1000, an ROE of 16.8559% and a debt to equity ratio of 0.1394.

With a -0.60% decrease, Dr Reddys Laboratories Ltd's share price is currently at ₹1,281.20. This development raises questions about the factors behind the decline. The stock's PE ratio is 19.1000, while the industry PE is 35.5773.

Dr Reddys Laboratories Ltd's share price has fallen by -0.07%, presenting both challenges and opportunities for investors. As of now, it's trading at ₹1,287.05, and market participants are assessing the implications. The stock has a PE ratio of 19.1000, an ROE of 16.8559% and a debt to equity ratio of 0.1394.

Climbing steadily, Dr Reddys Laboratories Ltd shares have ascended by 0.15%, reaching the current market price of ₹1,302.00. This ascent signifies increased investor sentiment. The stock has an ROE of 16.8559% and debt to equity ratio of 0.1394.